Opus plans to share initial data from the pediatric ... due to biallelic mutations in the LCA5 gene. It is an open-label, Phase 1/2 trial evaluating OPGx-LCA5. Efficacy endpoints include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback